Spineology, Inc. v. Wright Medical Technology Inc. (No. 2018-1276, 12/14/18) (Prost, Dyk, Moore)

Moore, J. Affirming denial of motion for attorney fees under 35 U.S.C. § 285. "[W]e caution future litigants to tread carefully in their complaints about district courts not doing enough." The Court also stated that a "district court need not, as [defendant] seems to urge, litigate to resolution every issue mooted by summary judgment to rule on a motion for attorney fees. And we need not, as [defendant] requests, get into the weeds on issues the district court never reached."

A full version of the text is available in PDF form.

Virntex Inc. v. Apple, Inc.  (No. 2017-2490, 12/10/18) (Newman, O'Malley, Chen)

O'Malley, J. Affirming Board decision in IPR of obviousness. Patent owner was collaterally estopped from relitigating the question of whether a reference was a printed publication. The Court also concluded that the patent owner "did not preserve the issue of whether inter partes review procedures apply retroactively to patents that were filed before Congress enacted the AIA."

A full version of the text is available in PDF form.

Novartis AG v. Ezra Ventures LLC (No. 2017-2284, 12/7/18) (Moore, Chen, Hughes)

Chen, J. Affirming decision that obviousness-type double patenting does not invalidate an otherwise validly obtained patent term extension under § 156.

A full version of the text is available in PDF form.

Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical (No. 2017-2173, -2175, -2176, -2178, -2179, -2180, -2182, -2183, -2184, 12/7/18) (Prost, Wallach, Chen)

Chen, J. Reversing decision on obviousness-type double patenting. Of the two patents at issue, one was filed prior to the URAA and entitiled to a term of 17 years from issue, and the other was filed after the URAA and entitled to a term of 20 years from the filing date. Due to the difference in terms, the latter of the two patents to issue was the first to expire. "The legal question we confront in this appeal is whether the law of obviousness-type double patenting requires a patent owner to cut down the earlier-filed, but later expiring, patent's statutorily-granted 17-year term so that it expires at the same time as the later-filed, but earlier expiring patent, whose patent term is governed under an intervening statutory scheme of 20 years from that patent's earliest effective filing date." Distinguishing Gilead, in which both patents had been filed after the URAA, the Court found that obviousness-type double patenting did not apply.

A full version of the text is available in PDF form.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.